N octuria is defined as 'the complaint that the individual has to wake at night one or more times to void'. The prevalence of nocturia increases with age. By 80 years of age, most people suffer from two or more episodes of nocturia per night. 1 It has a major impact on health, both physically and psychologically.
Nocturia negatively affects quality of life, as sleep disturbance results in daytime fatigue and drowsiness. Moreover, it is associated with cognitive dysfunction, depression and a sense of being unwell.
AETIOLOGY OF NOCTURIA
Nocturia can be a result of various behavioural, environmental or pathological conditions. Old age and cold weather can contribute to the problem. Behavioural causes may be related to anxiety, consumption of diuretics, excessive fluid ingestion, particularly caffeine and alcohol, or anorexia nervosa ( Figure 1 and Box 1).
Medical causes include congestive heart failure, stroke, diabetes mellitus, diabetes insipidus, urinary tract infections, sleep apnoea syndrome and peripheral oedema. Urological conditions that cause nocturia as a result of reduced nocturnal bladder capacity include bladder outlet obstruction from benign or cancerous enlargement of the prostate, overactive bladder and irritative bladder pathologies, ie bladder calculi and tumours (Box 1). 2
DIAGNOSIS OF NOCTURIA
Assessment of patients with nocturia begins with a focused history, physical examination and investigations. A detailed history helps to differentiate urological from medical causes. It is important to ask whether the patient is taking diuretics.
Investigations are suggested by the clinical evaluation. Simple tests such as urine analysis and blood indices are of paramount importance. A voiding diary is one of the key diagnostic tools for nocturia. Using the data provided in the voiding diary and calculating various indexes using different formulae will assist in establishing the type of nocturia.
NON-PHARMACOLOGICAL TREATMENT
Lifestyle change is the first step in the management of nocturnal polyuria. Patients should be encouraged to avoid (or at least to reduce) fluid intake in the evening. Alcohol and caffeinated drinks should be eliminated if possible. Simple advice to take diuretics during the day rather than at night might be helpful.
Patients diagnosed with primary polydipsia should be referred for psychiatric assessment and treatment. Wearing compression stockings and daytime leg elevation in patients with dependent oedema may alleviate this bothersome symptom.
Strict blood sugar control might be all that is needed to control the symptoms in diabetic patients. Treatment of diabetes insipidus needs careful evaluation and correction. In addition, continuous positive airway pressure may benefit patients with sleep apnoea syndrome associated with nocturia. Treatment of nephritic syndrome and optimisation of fluid balance in congestive heart failure will improve nocturia. Patients with metabolic disorders such as hyperkalaemia and hypercalcaemia should be investigated and treated accordingly.
PHARMACOLOGICAL TREATMENT
Several pharmacological therapies have been used in the treatment of nocturia, with varying degree of success. The choice of therapy depends on the primary aetiology; options include desmopressin acetate, antimuscarinic agents, melatonin, alpha-adrenergic blockers and diuretics.
Desmopressin acetate
Desmopressin (1-deamino-8-D-arginine vasopressin) is a synthetic analogue of the antidiuretic hormone, also known as vasopressin. It plays a key role in controlling the rate of urine production. 3 Desmopressin has been used in the treatment of neurogenic (pituitary) diabetes insipidus and nocturnal enuresis, and nocturia in patients with multiple sclerosis. In addition, desmopressin decreases nocturnal voiding in patients with autonomic bladder dysfunction and Parkinson's disease. In the NOCTUPUS trials, 33 per cent of men and 46 per cent of women with nocturia treated with desmopressin showed a ≥50 per cent reduction in the mean number of voids during the night. 3, 4 Desmopressin is generally well tolerated. 5 Side-effects include headache, nausea, peripheral oedema and dizziness, affecting 5-10 per cent of patients. 4 Mild hyponatraemia (Na >130mmol/l) occurs in most patients taking desmopressin, but is usually asymptomatic. Attention should be paid to signs of fluid overload and oedema induced by desmopressin.
Treatment with desmopressin should be initiated at a dose of 50-100g orally, with a weekly dose escalation to a maximum of 400g. Serum sodium should be checked three days after initiation of treatment and three days after any titration of the dose.
Desmopressin is also available in nasal, sublingual and parenteral formulations. 6 Although the former has been used successfully, its absorption is not predictable. The intranasal formulation provides 10g/spray, and can be used up to a maximum dose of 40g/day. Desmopressin should be avoided in patients with congestive heart failure, cirrhosis of the liver, renal failure and primary polydipsia.
Antimuscarinic agents
Muscarinic receptors in the bladder are normally stimulated by the release of acetylcholine from activated presynaptic cholinergic nerve cells, resulting in bladder contraction and a sense of urgency. Antimuscarinic agents, also referred to as 'anticholinergics', including Antimuscarinic agents are mainly used as bladder relaxants and considered to be the first-line treatment for symptoms of overactive bladder (OAB) syndrome. A few studies have showed a modest benefit of antimuscarinic agents in controlling nocturia associated with OAB.
Because of the abundance of muscarinic receptors throughout the body, the effects of antimuscarinic agents are not only limited to the bladder. Side-effects include dry mouth, constipation and headache. Oxybutynin and tolterodine can cross the blood-brain barrier, causing central nervous system effects such as hallucinations and dizziness. 2 In spite of these side-effects, the benefits of antimuscarinics seem to outweigh their risks.
Melatonin
Melatonin (N-acetyl-5-methoxytryptamine) is a hormone secreted by the pineal gland predominantly at night. Melatonin improves the quality of sleep and has a main role in maintaining the circadian rhythm in the body and therefore affecting, directly or indirectly, urine production at night. Melatonin secretion is impaired in the elderly, which can contribute to disruption of the circadian rhythm of micturition, leading to nocturia.
Melatonin, as a drug, has a short half-life (40-50 minutes) and has been shown to improve sleep patterns in older people. Drake et al. studied the effect of 2mg melatonin on elderly patients (age range 60-81 years) with nocturia associated with bladder outlet obstruction proven urodynamically. 6 There were fewer episodes of nocturia and an improvement in bother score related to nocturia with melatonin treatment.
Alpha-adrenergic blockers
Reduced nocturnal bladder capacity in elderly men may be secondary to bladder outlet obstruction caused by prostatic enlargement. Men with lower urinary tract symptoms often report nocturia as one of the most bothersome symptoms. Alphaadrenergic blockers such as tamsulosin and doxazosin improve nocturia in men with symptomatic prostatic enlargement. In a randomised, double-blind, placebocontrolled trial, Johnson et al. concluded that doxazosin, alone or combined with finasteride, significantly reduced the number of episodes of nocturia compared with placebo. 7
Diuretics
Taking diuretics six to eight hours before sleep is another possible option to control the polyuria type of nocturia; this prevents accumulation of water by forcing water out of the system before the early sleeping hours. However, the International Consultation on Incontinence committee has failed to recommend diuretics for the management of nocturia because of lack of published evidence. 8
CONCLUSION
Nocturia is a common problem, especially in the elderly. It may be the result of medical, urological or environmental conditions. A good history and examination can rule out many conditions and most of the symptoms can be controlled by behavioural therapy. However, referral to a specialist should be arranged if there is an underlying medical condition.
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